A formal proposal for a supplementary protection certificate (SPC) waiver to allow generics and biosimilars to be manufactured for export outside the European Union (EU) during the term of an SPC has been published by the European Commission. However, local off-patent industry association Medicines for Europe says the proposal does not go far enough in allowing production for ‘day one’ launches within the EU after SPC expiry.
Outlining its proposal, the Commission says the waiver is “for the exclusive purpose of exporting products to non-EU markets where...




